PMID- 17201619
OWN - NLM
STAT- MEDLINE
DCOM- 20070301
LR  - 20181113
IS  - 1044-5463 (Print)
IS  - 1557-8992 (Electronic)
IS  - 1044-5463 (Linking)
VI  - 16
IP  - 6
DP  - 2006 Dec
TI  - Safety and efficacy of rivastigmine in adolescents with Down syndrome: a 
      preliminary 20-week, open-label study.
PG  - 755-65
AB  - Individuals with Down syndrome (DS) exhibit a cholinergic deficiency similar to 
      that found in Alzheimer's disease. Cholinesterase inhibitors, used to treat 
      Alzheimer's disease, may improve cognitive function in individuals with DS. This 
      is the first investigation of the safety and efficacy of rivastigmine (an acetyl 
      and butyryl cholinesterase inhibitor) on specific cognitive domains in pediatric 
      DS. Eleven subjects with DS (ages 10-17 years) were treated with a liquid 
      formulation of rivastigmine. Four subjects experienced no adverse events (AEs). 
      Seven subjects reported AEs that were mild, transient and consistent with adverse 
      events typically noted with cholinesterase inhibitors. Significant improvements 
      were found in overall adaptive function (Vineland Adaptive Behavior Scales and 
      Clinician's Interview-Based Impression of Change), attention (Leiter Attention 
      Sustained tests A and B), memory (NEPSY: Narrative and Immediate Memory for Names 
      subtests) and language (Test of Verbal Expression and Reasoning and Clinical 
      Evaluation of Language Fundamentals-Preschool) domains. Improved language 
      performance was found across all functional levels. These results underscore the 
      need for larger, controlled studies employing a carefully constructed test 
      battery capable of measuring the full scope of performance across multiple 
      domains and a wide range of functional levels.
FAU - Heller, James H
AU  - Heller JH
AD  - Department of Surgery, Duke University Medical Center, Durham, North Carolina 
      27710, USA.
FAU - Spiridigliozzi, Gail A
AU  - Spiridigliozzi GA
FAU - Crissman, Blythe G
AU  - Crissman BG
FAU - Sullivan, Jennifer A
AU  - Sullivan JA
FAU - Eells, Rebecca L
AU  - Eells RL
FAU - Li, Jennifer S
AU  - Li JS
FAU - Doraiswamy, P Murali
AU  - Doraiswamy PM
FAU - Krishnan, K Ranga
AU  - Krishnan KR
FAU - Kishnani, Priya S
AU  - Kishnani PS
LA  - eng
GR  - M01 RR000030-430671/RR/NCRR NIH HHS/United States
GR  - M01-RR30/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Child Adolesc Psychopharmacol
JT  - Journal of child and adolescent psychopharmacology
JID - 9105358
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Phenylcarbamates)
RN  - PKI06M3IW0 (Rivastigmine)
SB  - IM
MH  - Adaptation, Psychological/drug effects
MH  - Adolescent
MH  - Attention/drug effects
MH  - Child
MH  - Cholinesterase Inhibitors/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Down Syndrome/*drug therapy/psychology
MH  - Female
MH  - Humans
MH  - Language
MH  - Male
MH  - Memory/drug effects
MH  - Patient Compliance
MH  - Phenylcarbamates/administration & dosage/adverse effects/*therapeutic use
MH  - Rivastigmine
MH  - Verbal Behavior/drug effects
PMC - PMC3129997
MID - NIHMS110077
EDAT- 2007/01/05 09:00
MHDA- 2007/03/03 09:00
PMCR- 2011/07/05
CRDT- 2007/01/05 09:00
PHST- 2007/01/05 09:00 [pubmed]
PHST- 2007/03/03 09:00 [medline]
PHST- 2007/01/05 09:00 [entrez]
PHST- 2011/07/05 00:00 [pmc-release]
AID - 10.1089/cap.2006.16.755 [doi]
PST - ppublish
SO  - J Child Adolesc Psychopharmacol. 2006 Dec;16(6):755-65. doi: 
      10.1089/cap.2006.16.755.